Wedbush Starts Audentes Therapeutics (BOLD) at Outperform
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Wedbush initiated coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Outperform rating and a price target of $20.
"BOLD’s AAV-based gene therapy programs are targeted to address significant unmet medical need in life-threatening rare diseases. With clinical readouts expected in 2017 from three wholly-owned programs backed by robust preclinical data, we view BOLD shares as a compelling opportunity," said analyst David M. Nierengarten.
Shares of Audentes Therapeutics closed at $14.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Raises Price Target on Microsoft (MSFT) to $65 Following 1Q Beat
- UPDATE: Stifel Downgrades SL Green Realty (SLG) to Hold
- Seaport Global Securities Upgrades Tutor Perini Corporation (TPC) to Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!